CLINICAL TRIALS PROFILE FOR RAPAFLO
✉ Email this page to a colleague
All Clinical Trials for RAPAFLO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00224107 ↗ | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo | Completed | Watson Pharmaceuticals | Phase 3 | 2005-05-01 | A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks. |
| NCT00224120 ↗ | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo | Completed | Watson Pharmaceuticals | Phase 3 | 2005-05-01 | A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks. |
| NCT00224133 ↗ | The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months | Completed | Watson Pharmaceuticals | Phase 3 | 2005-09-01 | A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety. |
| NCT00740779 ↗ | Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. | Completed | Watson Pharmaceuticals | Phase 2 | 2008-09-01 | The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo. |
| NCT00793819 ↗ | A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia | Completed | Watson Pharmaceuticals | Phase 2 | 2009-01-01 | Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH |
| NCT02220829 ↗ | Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy | Recruiting | Sir Mortimer B. Davis - Jewish General Hospital | Phase 3 | 2016-06-01 | Approximately 50%-95% of prostate cancer patients undergoing radiation therapy (RT) develop symptomatic urinary problems .These symptoms can significantly diminish a patient's quality of life during and shortly after therapy. Alpha1-blockers, such as Rapaflo, act to decrease resistance to urinary flow. This multi-institutional phase III trial is designed to compare standard of care versus preventive treatment with Rapaflo for prostate cancer patients, regardless of risk group, whose treatment consists of radical radiation therapy. We plan to recruit 188 patients across Quebec who will be randomized into two arms: rapaflo prescribed at start of radiation therapy or if/when symptoms appear. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RAPAFLO
Condition Name
Clinical Trial Locations for RAPAFLO
Trials by Country
Clinical Trial Progress for RAPAFLO
Clinical Trial Phase
Clinical Trial Sponsors for RAPAFLO
Sponsor Name
